Alpha-Lipoic Acid for Nerve Pain: The Doses and Routes Trials Used

The search results for alpha-lipoic acid and nerve pain agree that it works, usually at 600 mg a day, usually citing “studies”. We went back to the trials themselves, checked each one in PubMed on 30 October 2026, and sorted them by how the alpha-lipoic acid was given and what kind of nerve pain was treated.

That sorting changes the picture. Most of the positive results came from an intravenous drip given on weekdays in a clinic for three weeks. The longest capsule trial missed its main goal. And almost all of the evidence is for one condition, diabetic neuropathy, not for the sciatica, back pain and carpal tunnel pain the supplement is often sold for.

What alpha-lipoic acid is

Alpha-lipoic acid, also called thioctic acid, is a compound the body makes in small amounts and uses in the mitochondria. In diabetic nerve damage, oxidative stress is thought to be part of the injury, and alpha-lipoic acid is an antioxidant. That was the rationale for the trials below, most of which were run in Germany, Russia and Israel with a pharmaceutical product given by infusion or tablet. In the US it is sold as a dietary supplement.

The trials, sorted by route

Trial	People	How it was given	Result on symptoms
ALADIN (1995)	328, diabetic neuropathy	IV, 100, 600 or 1,200 mg, 3 weeks	600 and 1,200 mg better than placebo
SYDNEY (2003)	120, diabetic neuropathy	IV, 600 mg, 14 treatments	Better than placebo, 5.7 vs 1.8 points
ALADIN III (1999)	509, diabetic neuropathy	IV 3 weeks, then oral 1,800 mg/day for 6 months	No significant difference at day 19 or at 7 months
SYDNEY 2 (2006)	181, diabetic neuropathy	Oral, 600, 1,200 or 1,800 mg, 5 weeks	All doses better than placebo
NATHAN 1 (2011)	460, diabetic neuropathy	Oral, 600 mg, 4 years	Primary endpoint missed, p = 0.105

The drip results

The pooled analysis that most articles lean on combined four trials: ALADIN, ALADIN III, SYDNEY and NATHAN II, 1,258 patients in all. Every one used 600 mg a day by intravenous infusion, on weekdays, for three weeks. Against placebo, the symptom score for the feet (pain, burning, pins and needles and numbness) improved by 24.1% more, and 52.7% of patients improved by half or more against 36.9% on placebo. The difference first appeared after about eight days. The trials in that analysis were found by searching the database of the manufacturer, VIATRIS, which the paper states.

Look at the placebo arm in the first ALADIN trial: symptom scores fell 38.4% on placebo over three weeks. Nerve pain responds strongly to placebo, which is why a trial without one tells you very little.

The capsule results

SYDNEY 2 is the main oral trial with a positive result. 181 patients in Russia and Israel took 600, 1,200 or 1,800 mg by mouth, or placebo, for five weeks. Symptom scores fell 51%, 48% and 52% against 32% on placebo. Higher doses did not help more, but nausea, vomiting and vertigo increased with dose, and the authors concluded that 600 mg once a day “appears to provide the optimum risk-to-benefit ratio”.

NATHAN 1 asked the question most people buying capsules actually have: does taking it for years help? 460 patients took 600 mg a day by mouth or placebo for four years. The primary endpoint, a combined score of nerve impairment and seven nerve tests, showed no significant difference (p = 0.105). Some secondary impairment scores favoured alpha-lipoic acid. But the authors also noted that the primary measure “did not deteriorate significantly” in the placebo group, so there was little decline to prevent. Serious adverse events were reported in 38.1% on alpha-lipoic acid against 28.0% on placebo, although stopping because of poor tolerability did not differ between groups.

ALADIN III, which followed three weeks of drip with six months of tablets, found no significant difference in symptom scores between its groups at seven months.

A 2023 meta-analysis of ten oral trials, 1,242 patients, found benefits on symptom scores and patient satisfaction. It also found that for pain on a visual scale, vibration sense, lower-limb impairment and nerve conduction, oral alpha-lipoic acid “did not produce favorable results”.

The American Academy of Neurology’s 2022 guideline for painful diabetic neuropathy recommends offering tricyclic antidepressants, SNRIs, gabapentinoids or sodium channel blockers. Alpha-lipoic acid is not among its recommended treatments.

Sciatica and back pain: no placebo-controlled trial of it alone

This is where the supplement is often marketed, and where the evidence is thinnest. Every trial we found had at least one of three problems: no placebo, no control group, or other ingredients in the same treatment.

• Memeo 2008, 64 people with sciatica from a herniated disc: 600 mg alpha-lipoic acid against acetyl-L-carnitine for 60 days. Both groups improved. There was no placebo group.
• Abdelrahman 2021, 120 people with chronic lumbosacral radicular pain: everyone had pulsed radiofrequency treatment of the dorsal root ganglion, and half also took oral alpha-lipoic acid (1,800 mg a day for three weeks, then 600 mg for two). The alpha-lipoic acid group had higher success rates at three and six months. The abstract describes no placebo capsule.
• Battisti 2013, 98 people with chronic low back pain: a “prospective non-randomized open-label study” of alpha-lipoic acid plus superoxide dismutase, with no comparison group.
• Three more recent studies (Bonetti 2022, Latini 2023, Scaturro 2023) combine alpha-lipoic acid with palmitoylethanolamide and myrrh, with ozone therapy, or with acetyl-L-carnitine, resveratrol and vitamin D. With several ingredients given together, they cannot tell you what any one of them did.

Sciatica from a disc herniation often improves over weeks without any treatment. Without a placebo group, a study cannot separate that natural course from the supplement. A 2022 systematic review of alpha-lipoic acid for pain included seven trials outside diabetic neuropathy, but its meta-analysis was “conducted only with the studies using diabetic polyneuropathy”.

Carpal tunnel: two small surgical trials, mixed results

The two placebo-controlled carpal tunnel trials we found were both built around surgery:

• Monroy Guízar 2018, 20 adults: 600 mg a day for one month before surgery and two months after. Nerve conduction measures improved in the alpha-lipoic acid group. The Boston symptom questionnaire improved in both groups.
• Boriani 2017, 64 adults: alpha-lipoic acid for 40 days after surgery. It “did not improve nerve conduction velocity or Boston Carpal Tunnel score significantly”. Fewer patients had pillar pain, the soreness at the base of the palm after the operation.

Neither tested alpha-lipoic acid instead of treatment for carpal tunnel syndrome.

What US labels actually contain

The trial dose was 600 mg of racemic alpha-lipoic acid, a 50:50 mix of its R and S forms. We read the on-market labels in the NIH Dietary Supplement Label Database with lipoic acid in the product name, and kept the 242 where alpha-lipoic acid or R-lipoic acid was the only listed ingredient:

Amount per serving on the label	Label records
600 mg or more	53
Less than 600 mg	189
300 mg or less	172
R-lipoic acid products	28

Per-serving amounts ranged from 25 mg to 1,000 mg (the 1,000 mg product takes three capsules to get there). Many labels let you take more than one serving a day, so these are not daily totals, and the same product can appear more than once in the database. The point is that three of the four most common per-serving amounts, 100 mg, 300 mg and 200 mg, are a fraction of what the oral trials used. Only 600 mg, the second most common, matches it.

R-lipoic acid is sold as the more active form. The neuropathy trials above used the racemic mix, and we found no placebo-controlled trial of R-lipoic acid alone for nerve pain.

Safety, including one rare reaction worth knowing

In the trials, nausea, vomiting and vertigo increased with dose. The four-year NATHAN 1 trial recorded more serious adverse events on alpha-lipoic acid than placebo, as described above.

The rarer risk is insulin autoimmune syndrome, also called Hirata disease. The body makes antibodies against its own insulin, causing repeated episodes of low blood sugar, sometimes alternating with high readings after meals. A 2026 review says “an increasing number of cases have been attributed to” alpha-lipoic acid, and that susceptibility is linked to particular HLA genes (HLA-DRB1*04:06, 04:03 and 04:04). Most patients recover after stopping the trigger. If you take alpha-lipoic acid and start having shaky, sweaty, confused spells, especially if you do not have diabetes, it is worth telling your doctor that you take it.

Separately, anyone using insulin or sulfonylureas should talk to their doctor before starting it, because their diabetes treatment may need watching.

No product box on this page

The trials support a modest symptom benefit in diabetic neuropathy, mostly from intravenous treatment, and do not show that capsules help sciatica, back pain or carpal tunnel syndrome. That is not a basis for recommending a product, so there is none here. Persistent nerve pain, numbness or weakness also needs a diagnosis first. The cause shapes the treatment, and some causes, such as nerve compression or vitamin B12 deficiency, have specific treatments of their own.

The bottom line

Alpha-lipoic acid has the best evidence of any supplement for the symptoms of diabetic neuropathy, but that evidence is strongest for three weeks of intravenous treatment. Capsules have one positive five-week trial and one four-year trial that missed its main goal. For sciatica, back pain and carpal tunnel syndrome, the trials are too small, too uncontrolled or too mixed with other ingredients to show an effect of alpha-lipoic acid itself. Most US capsules contain less than the trial dose, and a rare reaction can cause serious low blood sugar.